Attached files

file filename
EX-32 - CERTIFICATION PURSUANT TO - PURA NATURALS, INC.ex32.htm
EX-32 - PURA NATURALS, INC.ex32_1.htm
EX-32 - PURA NATURALS, INC.ex31_2.htm
EX-31 - PURA NATURALS, INC.ex31_1.htm
EX-21 - PURA NATURALS, INC.ex21.htm

 

 

 


 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For Quarter Ended:   September 30, 2019

 

Commission File Number 000-54888

 

PURA NATURALS, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   20-8496798
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification No.)

 

23101 Lake Center Drive, Suite 100

Lake Forest, CA 92630

 (Address of principal executive offices) (Zip Code)

 

(855) 326-8537

  (Registrant's telephone number, including area code)

 

NA.

(Former name, former address and former fiscal year, if change since last report)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes        No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes        No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

 

Large accelerated filer    Accelerated filer 
     
Non-accelerated filer    Smaller reporting company 
(Do not check if a smaller reporting company)    
    Emerging growth company 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes        No

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(1) of the Exchange Act    

 

The number of shares of the registrant's only class of common stock issued and outstanding as of January 21, 2020 was 1,448,933,660 shares.

 

 

 1 
 

 

 

 

 

 

PART I

FINANCIAL INFORMATION

 

 

TABLE OF CONTENTS

 

 

 

PART I   Page
     
Item 1. Financial Statements 3
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
     
Item 4. Controls and Procedures 24
     
PART II    
     
Item 1. Legal Proceedings 24
     
Item 1A. Risk Factors 24
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
     
Item 3. Defaults Upon Senior Securities 25
     
Item 4. Mine Safety Disclosures 25
     
     
Item 5. Other Information 26
     
Item 6. Exhibits 26
     
  Signatures 26

 

 

 

 

 2 
 

 

 

 

 

PURA NATURALS, INC.

Consolidated Balance Sheets

 

   September 30,  December 31,
   2019  2018
    (unaudited)      
ASSETS          
           
CURRENT ASSETS          
   Cash  $-   $29,777 
   Accounts receivable, net of allowance of $33,448 and $33,448   82,768    52,001 
   Inventory   104,477    115,171 
   Prepaid expenses and other current assets   -    106,010 
      Total Current Assets   187,245    302,959 
OTHER ASSETS          
Intangible assets, net   583,225    657,950 
      Total Other Assets   583,225    657,950 
      TOTAL ASSETS  $770,470   $960,909 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
CURRENT LIABILITIES          
   Accounts payable  $547,265   $496,213 
   Accrued expenses   678,136    822,622 
   Due to related parties   863,357    594,423 
   Deferred revenues   25,000    25,000 
   Notes payable   91,677    103,722 
   Convertible note payable, net of discount of $19,353 and $272,633   873,419    775,690 
   Derivative liabilities   410,261    1,209,150 
      Total Current Liabilities   3,489,115    4,026,820 
      TOTAL LIABILITIES   3,489,115    4,026,820 
           
Commitments and contingencies          
           

STOCKHOLDERS' DEFICIT

 

          
   Common stock, $0.001 par value, 1,500,000,000 shares authorized, 1,148,627,103 and          
      483,552,395 shares issued and outstanding at September 30, 2019 and December 31, 2018   1,148,626    483,551 
   Additional paid-in capital   12,092,684    10,362,669 
   Accumulated deficit   (15,959,955)   (13,912,131)
      TOTAL STOCKHOLDERS' DEFICIT   (2,718,645)   (3,065,911)
      TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT  $770,470   $960,909 

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 

 

 3 
 

 

 

Pura Naturals, Inc.

Consolidated Statements of Operations

(Unaudited)

 

   Three Months Ended September 30,  Nine Months Ended September 30,
   2019  2018  2019  2018
             
             
Sales  $133,349   $156,486   $294,045   $301,858 
Cost of goods sold   47,935    72,277    175,646    164,959 
GROSS PROFIT   85,414    84,209    118,399    136,899 
                     
OPERATING EXPENSES                    
   Selling expenses   70,489    154,472    207,262    245,372 
   General and administrative expenses   570,634    450,362    2,073,460    1,734,666 
      Total Operating Expenses   641,123    604,834    2,280,722    1,980,038 
LOSS FROM OPERATIONS   (555,709)   (520,625)   (2,162,323)   (1,843,139)
                     
OTHER INCOME (EXPENSE)                    
   Interest expense   (120,933)   (303,106)   (501,394)   (957,959)
   Change in value of derivative liability   505,679    (2,567,099)   615,893    (3,028,388)
      Total Other Income (Expense)   384,746    (2,870,205)   114,499    (3,986,347)
LOSS BEFORE INCOME TAX PROVISION   (170,963)   (3,390,830)   (2,047,824)   (5,829,486)
                     
Income tax provision   -    -    -    - 
                     
NET LOSS  $(170,963)  $(3,390,830)  $(2,047,824)  $(5,829,486)
                     
Weighted average shares outstanding                    
BASIC AND DILUTED   961,726,661    137,736,958    774,134,242    78,754,180 
                     
Loss per share                    
BASIC AND DILUTED  $(0.00)  $(0.02)  $(0.00)  $(0.07)

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 

 4 
 

 

 

 

Pura Naturals, Inc.

Consolidated Statements of Stockholders’ Deficit

(Unaudited)

 

                
         Additional     Total
   Common Stock  Paid-in  Accumulated  Stockholders'
   Shares  Amount  Capital  Deficit  Deficit
Balance, December 31, 2018   483,552,395   $483,551   $10,362,669   $(13,912,131)  $(3,065,911)
                          
Common stock issued for notes principal and accrued interest conversions   75,383,269    75,384    67,595         142,979 
Common stock issued for services and deferred compensation   220,143,169    220,143    447,472         667,615 
Fair value of options             235,190         235,190 
Derivative liabilities extinguished on conversion             132,530         132,530 
Net loss                  (392,003)   (392,003)
                          
Balance, March 31, 2019   779,078,833    779,078    11,245,456    (14,304,134)   (2,279,600)
                          
Common stock issued for notes principal and accrued interest conversions   41,760,000    41,760    660         42,420 
Common stock issued for services   65,000,000    65,000    130,000         195,000 
Fair value of options             235,190         235,190 
Derivative liabilities extinguished on conversion             86,688         86,688 
Net loss                  (1,484,858)   (1,484,858)
                          
Balance, June 30, 2019   885,838,833    885,838    11,697,994    (15,788,992)   (3,205,160)
                          
Common stock issued for notes principal and accrued interest conversions   123,980,651    123,981    (12,866)        111,115 
Common stock issued for services   138,807,619    138,807    152,689         291,496 
Fair value of options             175,089         175,089 
Derivative liabilities extinguished on conversion             79,778         79,778 
Net loss                  (170,963)   (170,963)
                          
Balance, September 30, 2019   1,148,627,103   $1,148,626   $12,092,684   $(15,959,955)  $(2,718,645)
                          
                          
                          
                          
                          
Balance, December 31, 2017   39,114,709   $39,115   $5,710,270   $(7,325,684)  $(1,576,299)
                          
Common stock issued for notes principal and accrued interest conversions   5,317,460    5,317    204,508         209,825 
Common stock issued for cash   83,333    83    4,917         5,000 
Common stock issued to extend due date of convertible debt   300,000    300    25,200         25,500 
Common stock issued for services   200,000    200    32,200         32,400 
Fair value of options             120,567         120,567 
Derivative liabilities extinguished on conversion             132,573         132,573 
Net loss                  (2,431,302)   (2,431,302)
                          
Balance, March 31, 2018   45,015,502    45,015    6,230,235    (9,756,986)   (3,481,736)
                          
Common stock issued for notes principal and accrued interest conversions   25,931,888    25,932    191,604         217,536 
Fair value of options             60,101         60,101 
Derivative liabilities extinguished on conversion             449,305         449,305 
Net loss                  (7,354)   (7,354)
                          
Balance, June 30, 2018   70,947,390    70,947    6,931,245    (9,764,340)   (2,762,148)
                          
Common stock issued for notes principal and accrued interest conversions   225,762,689    225,764    266,136         491,900 
Fair value of options             60,101         60,101 
Derivative liabilities extinguished on conversion             1,398,727         1,398,727 
Net loss                  (3,390,830)   (3,390,830)
                          
Balance, September 30, 2018   296,710,079   $296,711   $8,656,209   $(13,155,170)  $(4,202,250)

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 5 
 

 

 

 

Pura Naturals, Inc.

Consolidated Statements of Cash Flows

(Unaudited) 

 

 

   Nine Months Ended September 30,
   2019  2018
       
       
OPERATING ACTIVITIES          
   Net loss  $(2,047,824)  $(5,829,486)
   Adjustments to reconcile net loss to          
      net cash used in operating activities:          
         Amortization of intangible assets   74,725    75,059 
         Amortization of debt discounts and original issue discounts   369,280    780,632 
         Penalty interest resulted in principal increase   58,000    59,520 
         Change in fair value of derivative instruments   (615,893)   3,028,388 
         Fair value of options vested   645,469    240,769 
         Common stock issued for services   697,746    32,400 
         Common stock issued for convertible note due date extension   -    25,500 
      Change in current assets and liabilities          
         Accounts receivable   (30,767)   (1,628)
         Inventory   10,694    (35,723)
         Due from related parties   -    (20,500)
         Due to related parties   268,934    143,991 
         Prepaid expenses and other assets   106,010    108,696 
         Accounts payable   51,052    148,850 
         Accrued expenses   317,773    742,886 
Net Cash Used in Operating Activities   (94,801)   (500,646)
           
INVESTING ACTIVITIES          
   Payment for intangible assets   -    (1,950)
Net Cash Used in Investing Activities   -    (1,950)
           
FINANCING ACTIVITIES          
   Proceeds from sale of common stock   -    5,000 
   Proceeds from issuance of convertible notes payable   116,000    320,000 
   Proceeds from issuance of notes payable   22,515    128,500 
   Payments on convertible notes payable   (38,931)   - 
   Payments on notes payable   (34,560)   (10,316)
Net Cash Provided by Financing Activities   65,024    443,184 
           
NET DECREASE IN CASH   (29,777)   (59,412)
           
CASH, BEGINNING OF PERIOD   29,777    67,422 
           
CASH, END OF PERIOD  $-   $8,010 
           
CASH PAID FOR:          
   Interest  $12,911   $4,368 
   Income taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:          
   Common stock issued for convertible note payable and accrued interest  $296,514   $919,261 
   Debt discount for new issuances due to derivative feature of convertible note  $116,000   $320,000 
   Common stock issued for deferred compensation  $456,365   $- 
   Derivative liability extinguished on conversion  $298,996   $1,980,606 

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements

 

 6 
 

 

 

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

Pura Naturals, Inc.

 

 

 

 

Note 1 – Organization and Basis of Presentation

 

Organization and Line of Business

 

Pura Naturals, Inc. (formerly Yummy Flies, Inc.) (The "Company" or "Pura - CO") was incorporated under the laws of the State of Colorado on December 26, 2005.  On November 17, 2016, the Company changed its name from Yummy Flies, Inc. to Pura Naturals, Inc.

 

Pura Naturals, Inc., ("Pura - DE") was incorporated on April 20, 2015 under the laws of the state of Delaware.  Prior to incorporating in Delaware, the Company was incorporated on October 21, 2013 under the laws of the state of Nevada as a limited liability company.  On June 30, 2015, the Company exchanged membership interests in the Nevada Corporation for common stock of the Pura - DE.

 

Effective July 18, 2016, the Company entered into that certain share exchange agreement by and among the Company, Pura - DE") and certain shareholders of Pura – DE  (the "PURA Shareholders").  Pursuant to the Share Exchange Agreement, the Company exchanged the outstanding common and preferred stock of Pura - DE held by the PURA Shareholders for shares of common stock of the Company.  At the closing date, Robert Lee, the holder of 30,536,100 shares of common stock, agreed to cancelation of such shares.  Other than Robert Lee, shareholders of Company common stock held 7,625,700 shares.  Also on the closing date, the Company issued 23,187,876 shares of common stock to the PURA shareholders.   In addition, shares issuable under outstanding options of Pura – DE will be exercisable into shares of common stock of the Company, pursuant to the terms of such instruments.  As a result of the share exchange agreement and the other transactions contemplated there under, Pura - DE became a wholly owned subsidiary of the Company.

 

The Company is engaged in the marketing and sales of consumer products through the use of direct sales, brokers and distributors to wholesalers, mass merchandisers, retail stores and on the internet.

 

The unaudited financial statements were prepared by the Company, pursuant to the rules and regulations of the Securities Exchange Commission ("SEC"). The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") were omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements and footnotes included in the Company's Annual Report on Form 10-K filed with the SEC on July 24, 2019. The results for the nine months ended September 30, 2019, are not necessarily indicative of the results to be expected for the year ending December 31, 2019.

 

 

Note 2 - Summary of Significant Accounting Policies

 

Revenue Recognition

 

The Company recognizes revenue from sales of consumer products to wholesalers, mass merchandisers and retail stores . In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (Topic 606) “Revenue from Contracts with Customers.” Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605). The new standard’s core principal is that an entity will recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring good or services to a customer. The principals in the standard are applied in five steps: 1) Identify the contract(s) with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the entity satisfies a performance obligation.

 

ASU No. 2014-09, Revenue from Contracts with Customers ("Topic 606"), became effective for us on January 1, 2018. We applied the "modified retrospective" transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily through distributors, and we have no significant post delivery obligations, this did not result in a material recognition of revenue on our accompanying consolidated financial statements for the

 

 7 
 

 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

  

  

cumulative impact of applying this new standard. We made no adjustments to our previously-reported total revenues, as those periods continue to be presented in accordance with our historical accounting practices under Topic 605, Revenue Recognition.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation . FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee's requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees. There were 8,193,750 and 8,193,750 options outstanding as of September 30, 2019 and December 31, 2018, respectively.

 

Basic and Diluted Earnings (Loss) Per Share

 

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share . Basic earnings per share ("EPS") is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. The following potentially-dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive.

 

   September 30,  September 30,
   2019  2018
Options   8,193,750    8,193,750 
Warrants   5,000,000    - 
Convertible notes   1,599,176,689    154,137,853 
Total   1,612,370,439    162,331,603 
           

 

 Reclassification

 

Certain amounts in the prior period financial statements were reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.

 

Recent Accounting Pronouncements

 

In June 2018, the FASB issued Accounting Standards Update (“ASU”) ASU 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to nonemployees with the requirements for share-based payments granted to employees. ASU 2018-07 is effective on January 1, 2019. Early adoption is permitted. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements as the Company did not have any leases covered by this new ASU.

 

 

 8 
 

 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

  

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

 

Note 3 – Going Concern

 

The Company's consolidated financial statements were prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has incurred losses from operations since its change of ownership, management and line of business on July 18, 2016. Management recognizes successful business operations and the Company's transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue adequate to support its cost structure. These conditions raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of uncertainties. 

 

The Company incurred losses from operations of $2,162,323 for the nine months ended September 30, 2019 and $3,394,068 for the year ended December 31, 2018, and had an accumulated deficit of $15,959,955 at September 30, 2019. In addition, the Company used cash in operating activities of $94,801 for the nine months ended September 30, 2019. These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

While the Company is attempting to establish an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern, the Company's cash position may not be adequate to support the Company's daily operations. Management intends to raise additional funds by seeking equity and/or debt financing; however there can be no assurances that it will be successful in those efforts. The ability of the Company to continue as a going concern is dependent upon the Company's ability to obtain financing, further implement its business plan, and generate revenues.

 

There are significant risks and uncertainties which could negatively affect the Company's operations. These are principally related to (i) the absence of a distribution network for the Company's products, (ii) the absence of any significant commitments or firm orders for the Company's products. The Company's limited sales to date for the Company's products make it impossible to identify any trends in the Company's business prospects. Accordingly, there can be no assurance that we will be able to pay obligations which we may incur in the future.

 

The Company's only sources of additional funds to meet continuing operating expenses, fund additional development and fund additional working capital are through the sale of securities and/or debt instruments. We are actively seeking additional debt or equity financing, but no assurances can be given that such financing will be obtained or what the terms thereof will be. The Company may need to discontinue a portion or all of our operations if the Company is unsuccessful in generating positive cash flow or financing for the Company's operations through the issuance of securities.

 

The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

 Note 4 – Intangible Assets

 

The following are the details of intangible assets at September 30, 2019 and December 31, 2018:

 

 

   September 30,  December 31,
   2019  2018
Licenses  $996,346   $996,346 
Trademarks   13,055    13,055 
    1,009,401    1,009,401 
Less accumulated amortization   (426,176)   (351,451)
   $583,225   $657,950 
           

 

 

 9 
 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

Amortization expense for the nine months ended September 30, 2019 and 2018 was $74,725 and $75,059, respectively.

 

The following summarizes estimated future amortization expense as of September 30, 2019 related to intangible assets:

 

Twelve months ending September 30:
 2020   $100,883 
 2021    100,883 
 2022    100,883 
 2023    100,883 
 2024    100,883 
 Thereafter    78,810 
     $583,225 
        

 

Note 5 –Related Party Transactions

 

The Company has balances outstanding that are due from affiliated companies and payable to affiliated companies.  These amounts are payable upon demand and are non-interest bearing. 

 

Due to Related Parties - Advanced Innovative Recovery Technologies, Inc.

 

During the nine months ended September 30, 2019 and 2018, the overhead allocation charged to the Company from Advanced Innovative Recovery Technologies, Inc. a stockholder of the Company, was $90,000 and $80,000, respectively for office space provided and other items such as minor warehouse space, office / warehouse supplies and resource function allocation. In addition there was $46,186 and $60,300, respectively, of payroll allocated from AirTech to Company for the nine months ended September 30, 2019 and 2018. The amounts charged from Advanced Innovative Recovery Technologies, Inc, included in cost of goods sold was $125,082 and $110,985 of the total cost of goods sold the nine months ended September 30, 2019 and 2018, respectively. Amounts owed to Advanced Innovative Recovery Technologies, Inc as of September 30, 2019 and December 31, 2018 was $857,850 and $588,916, respectively.

 

Due to Related Parties – B3 LLC

 

B3, LLC is an inactive subsidiary of Advanced Innovative Recovery Technologies, Inc. Amount due to B3, LLC as of September 30, 2019 and December 31, 2018 was $5,507 and $5,507 respectively.

 

Due to Related Parties - Officers

 

As September 30, 2019 and December 31, 2018, the Company had $178,288 and $479,937 (which had been netted against $56,269 notes receivable and advances to the officers that the Company) of accrued salaries due to four officers which is included in accrued expenses.

 

Note 6 - Fair Value Measurement

 

Fair Value of Financial Instruments

 

For certain of the Company’s

 

 10 
 

 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

For certain of the Company’s financial instruments, including cash and equivalents, restricted cash, accounts receivable, advances to suppliers, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities.

 

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

 

·Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

 

·Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

·Level 3 inputs to the valuation methodology us one or more unobservable inputs which are significant to the fair value measurement.

 

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

 

The Company uses Level 3 inputs for its valuation methodology for derivative liabilities as their fair values were determined by using the Black-Scholes pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. At September 30, 2019 and December 31, 2018, the Company identified the following liabilities that are required to be presented on the balance sheet at fair value:

 

    Fair Value   Fair Value Measurements at
    As of   September 30, 2019
Description   September 30, 2019   Using Fair Value Hierarchy
        Level 1   Level 2   Level 3
Conversion feature on convertible notes and warrants $ 410,261 $ - $ - $ 410,261
                 
                 
    Fair Value   Fair Value Measurements at
    As of   December 31, 2018
Description   December 31, 2018   Using Fair Value Hierarchy
        Level 1   Level 2   Level 3
Conversion feature on convertible notes and warrants $ 1,209,150 $ - $ - $ 1,209,150
                 

 

The related gain (loss) on change in fair value of derivatives totaled $615,893 and $(3,028,388) for the nine months ended September 30, 2019 and 2018, respectively.

 

 11 
 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

Note 7 -  Derivative Liabilities

 

The Company identified conversion features embedded within its convertible debt. The Company has determined that the conversion feature of the convertible note represents an embedded derivative since the notes are convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt and the embedded conversion feature must be bifurcated from the debt host and accounted for as a derivative liability. Due to the lack of available common shares for all conversions, convertible notes with a fixed conversion price as well as warrants were categorized as a derivative.

 

 

Therefore, the fair value of the derivative instruments was recorded as liabilities on the balance sheet with the corresponding amount recorded as discounts to the notes. Such discounts will be accreted from the issuance date to the maturity date of the notes. The change in the fair value of the derivative liabilities will be recorded in other income or expenses in the statement of operations at the end of each period, with the offset to the derivative liabilities on the balance sheet. The fair value of the embedded derivative liabilities on the convertible notes were determined using the Black-Scholes valuation model on the issuance dates with the assumptions in the table below.

 

The change in the fair value of the Company's derivative liabilities from December 31, 2018 to September 30, 2019 is as follows:

 

Derivative liability balance, December 31, 2018  $1,209,150 
Discount on debt   116,000 
Reclass to equity due to conversions   (298,996)
Fair value mark to market adjustments   (615,893)
Derivative liability balance, September 30, 2019  $410,261 
      

 

The fair value's at the commitment dates and re-measurement dates for the convertible debt and warrants treated as derivative liabilities are based upon the following estimates and assumptions made by management at September 30, 2019 and December 31, 2018:

 

      September 30,     December 31,
      2019     2018
             
Stock price   $    0.002 – 0.008     $    0.003 - 0.043 
Risk free rate        1.71% -2.59%         1.96%  - 2.70% 
Volatility        0% - 323%         93% - 455% 
Conversion/ Exercise price   $    0.0004 - 0.0056    $    .0016 - 0.0093 
Terms (years)        0.0027-2.17         0.0027-2.92 
Dividend rate        0%        0%

 

 

 

 12 
 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

 For the Nine Months Ended September 30, 2019

 

Note 8 – Convertible Notes Payable

Convertible notes payable at September 30, 2019 and December 31, 2018 are as follows:

   September 30,  December 31,
   2019  2018
Dated April 7, 2017 for $570,000; accrues interest at 0% per annum; due January 7, 2018 (the holder of the note has not declared a default); secured by 500,000 shares of the Company's common stock; convertible into common stock at 75% of the average of the 3 lowest trading prices 5 days prior to conversion (currently in default).  $18,039   $97,256 
Dated July 14, 2017 for $330,000 with debt issuance costs of $30,000; accrues interest at 0% per annum; due April 17, 2018; convertible into common stock at 65% of the lowest trading price 30 days prior to conversion (currently in default).   330,000    330,000 
 Dated July 5, 2017 for $220,000 with debt issuance costs of $20,000; accrues interest at 8% per annum; due January 6, 2018; convertible into common stock at 60% of the average of the 3 lowest trading prices 5 days prior to conversion (currently in default).   5,458    5,458 
 Dated September 12, 2017 for $160,500 with debt issuance costs of $10,500; accrues interest at 12% per annum; due September 12, 2018; convertible into common stock at 50% of the lowest trading price 20 days prior to conversion (currently in default).   11,024    48,335 
 Dated December 18, 2017 for $125,000 with debt issuance costs of $16,250; accrues interest at 4.25% per annum; due October 23, 2018; convertible into common stock at 61% of the lowest trading price 15 days prior to conversion (currently in default).   40,000    98,674 
 Dated March 6, 2018 for $126,000 with debt issuance costs of $6,000; accrues interest at 8% per annum; due March 6, 2019; convertible into common stock at 60% of the lowest trading price 20 days prior to conversion (currently in default).   -    18,600 
 Dated October 8, 2018 for $50,000 with debt issuance costs of $1,000; accrues interest at 8% per annum; due April 8, 2019; convertible into common stock at the lower of 80% of the lowest trading price 5 days prior to conversion or $0.0065 (currently in default).   50,000    50,000 
 Dated October 8, 2018 for $50,000 with debt issuance costs of $1,000; accrues interest at 8% per annum; due April 8, 2019; convertible into common stock at the lower of 80% of the lowest trading price 5 days prior to conversion or $0.0065 (currently in default).   50,000    50,000 
 Dated October 8, 2018 for $200,000; accrues interest at 0% per annum; due April 8, 2019; convertible into common stock at 90% of the lowest trading price 5 days prior to conversion (currently in default).   200,000    200,000 
 Dated November 15, 2018 for $150,000 with debt issuance costs of $20,000; accrues interest at 0% per annum; due August 15, 2019; convertible into common stock at $0.005 per share. The Company also issued the investor 5,000,000 warrants in connection with this convertible note (currently in default).   87,251    150,000 

Dated January 22, 2019 for $63,000 (principal balance increased by $31,500 due to a penalty provision in the convertible note agreement); accrues interest at 12% per annum; due November 15, 2019 (as of the filing date, this note has been fully converted into shares of common stock); convertible into common stock at 61% of the average of the 2 lowest trading prices 10 days prior to conversion.

   21,500    - 
Dated March 4, 2019 for $53,000 (principal balance increased by $26,500 due to a penalty provision in the convertible note agreement); accrues interest at 12% per annum; due December 31, 2019 (currently in default); convertible into common stock at 61% of the average of the 2 lowest trading prices 10 days prior to conversion.   79,500    - 
    892,772    1,048,323 
Less debt discount   (19,353)   (272,633)
   $873,419   $775,690 
           

All of the above convertible notes payable are unsecured with the exception of the April 7, 2017 note which is secured by 500,000 shares of the Company’s common stock.

 

 13 
 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

 

The discounts on convertible notes payable arise from the conversion features of certain convertible notes being treated as derivative liabilities (see Note 7). In addition, the discounts also includes debt issuance costs. The discounts are being amortized over the terms of the convertible notes payable.  Amortization of debt discounts during the nine months ended September 30, 2019 and 2018 amounted to $369,280 and $780,632, respectively, and is recorded as interest expense in the accompanying consolidated statements of operations. The unamortized discount balance for these notes was $19,353 as of September 30, 2019, which is expected to be amortized over the next 12 months.

A summary of the activity in the Company's convertible notes payable is provided below:

 

Balance, December 31, 2018  $775,690 
Issuance of new convertible notes for cash   116,000 
Issuance of new convertible notes for penalty   58,000 
Repayment of convertible notes in cash   (38,931)
Converted into shares of common stock   (290,620)
Debt discount on new notes   (116,000)
Amortization of debt discounts   369,280 
Balance, September 30, 2019  $873,419 
      

 

Note 9 – Notes Payable

 

Notes payable at September 30, 2019 and December 31, 2018 are as follows:

   September 30,  December 31,
   2019  2018
Dated August 10, 2018 for $52,500 with debt issuance costs of $2,500; accrues interest at 0% per annum; unsecured; due on November 10, 2018 (currently in default).  $52,500   $52,500 
 Dated July 10, 2018 for $50,000; accrues interest at 30% per annum; unsecured; due on January 10, 2019 (currently in default).   25,000    40,000 
 Dated May 21, 2018 for $28,500; secured by virtually all the Company's assets; daily repayments of $165 for 246 days   -    11,222 
 Dated March 26, 2019 for net proceeds of $22,515; daily repayments of $170 for 248 days; unsecured; guaranteed by an officer of the Company.   14,177    - 
   $91,677   $103,722 

 

 

 14 
 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

Note 10 – Stockholders' Equity

 

Common stock

 

On January 31, 2019, the Company held an Annual Meeting of Stockholders (the "Annual Meeting"), at which the Company's stockholders approved an amendment to the Company's articles of incorporation ( the "Certificate of Incorporation") and adopted Company's Amended and Restated Articles of Incorporation (the "Certificate of Amendment") to increase the authorized shares of the Company's common stock from 500,000,000 to 1,500,000,000 and to authorize a reverse split of the Company's commons stock in a ratio of between 1 to 5 and 1 to 50 at the Board's discretion.

 

During nine months ended September 30, 2019, the Company issued shares of common stock as follows:

 

·241,123,920 shares for the conversion of $290,620 of convertible notes payable and $5,894 of accrued interest;

 

·358,950,788 shares for executive compensation of $959,111 of which $502,746 was for services rendered in 2019 and $456,365 was for services rendered prior to 2019 that was previously accrued. The value of the shares were determined based on a 25% discount to the closing stock price on the grant date; and

 

·65,000,000 shares to employees and consultants for services rendered of $195,000. The value of the shares was determined based on the market price on the date of issuance.

 

During the nine months ended September 30, 2018, the Company issued shares of common stock as follows:

     
·  

300,000 shares valued at $25,500 for extension of due date;

 

·  

257,012,037 shares for the conversion of $919,261 of convertible notes payable;

in payment of convertible notes (See Note 8)

 

·

 

 

83,333 shares for $5,000 cash; and

 

·   200,000 shares valued at $32,400 for employment agreement.

 

 

 15 
 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

 

Stock options

 

The following is a summary of stock option activity:

 

            Weighted    
        Weighted   Average    
        Average   Remaining   Aggregate
    Options   Exercise   Contractual   Intrinsic
    Outstanding   Price   Life   Value
Outstanding, December 31, 2018   8,193,750 $               0.001   3.70    
Granted   -            
Forfeited   -            
Exercised   -            
Outstanding, September 30, 2019   8,193,750 $               0.001   2.95    
Exercisable, September 30, 2019   2,568,750 $               0.001   2.72 $ -
                 

 

The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $645,469 and $249,969 during nine months ended September 30, 2019 and 2018, respectively. At September 30, 2019, the unamortized stock option expense was $537,145 which will be amortized to expense through October 1, 2021 and when certain milestone are met.

 

 

 

Warrants

 

In connection with note issued in 2018, 5,000,000 warrants were issued on November 15, 2018. The warrants have a 3 year life and have an exercise price of $0.01. In addition, if the market price of one warrant share is greater than the exercise price, the holder may elect to receive warrant shares, in lieu of a cash exercise, equal to the value of the warrant determined as follows:

 

X = Y (A-B)/A

 

where X = the number of warrant shares to be issued to holder;

 

Y = the number of warrant shares that the holder elects to purchase under this warrant

A = the market price

B = exercise price

 

The warrants were valued for $23,347 and recorded as derivative and debt discount as the warrants were tainted by other convertible notes with variable conversion price. The intrinsic value of the 5,000,000 warrants as of September 30, 2019 is $0.

 

 

Note 11 - Concentrations

 

The Company had certain customers whose accounts receivable balances individually represented 10% or more of the Company's total accounts receivable, as follows:

 

At September 30, 2019, five customer accounted for 24%, 16%, 16%, 13% and 11% of accounts receivable. At December 31, 2018, two customers accounted for 38% and 14% of accounts receivable. 

 

 

 16 
 

 

Pura Naturals, Inc.

Notes to Unaudited Consolidated Financial Statements

For the Nine Months Ended September 30, 2019

 

The Company had certain vendors whose accounts payable balances individually represented 10% or more of the Company's total accounts payables.

 

At September 30, 2019, one vendor accounted for 14% of accounts payable. At December 31, 2018, no vendor accounted for 10% of accounts payable. 

 

 

Note 12 – Commitments and Contingencies

 

From time to time, the Company is involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party for which management believes the ultimate outcome would have a material adverse effect on the Company's financial position.

 

In lieu of cash of $60,345 for outstanding attorney invoices, 6,611,200 common shares are to be issued. A liability of $60,345 was recorded as of September 30, 2019 and December 31, 2018 which will be offset when common shares are issued.

 

 

Note 13 - Subsequent Events

 

Subsequent to September 30, 2019 the Company had the following :

 

 

·Issued 300,306,557 shares of common stock for the conversion of $79,100 of convertible notes and $6,036 of accrued interest.

 

 

 17 
 

 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion should be read in conjunction with our financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the "safe harbor"   provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

 

Overview and History

 

We were incorporated on December 26, 2005, in the State of Colorado under the name "Yummieflies.com Inc."  In March 2010, we filed an amendment to our Articles of Incorporation changing our name to "Yummy Flies, Inc."  In November 2016, we filed an amendment to our Articles of Incorporation changing our name to "Pura Naturals, Inc."  In September 2010, we engaged in a forward split of our issued and outstanding Common Stock whereby nine (9) shares of Common Stock were issued in exchange for every one (1) share then issued and outstanding.  In addition, in November 2016, we engaged in a forward split of our issued and outstanding Common Stock whereby 3.7 shares of Common Stock were issued in exchange for every one (1) share then issued and outstanding.  All references to our issued and outstanding Common Stock in this Report are presented on a post-forward split basis unless otherwise indicated.

 

Effective July 18, 2016, the Company entered into that certain Share Exchange Agreement by and among the Company, Pura Naturals, Inc., PURA and the PURA Shareholders.  Pursuant to the Share Exchange Agreement, the Company exchanged the outstanding common and preferred stock of PURA held by the PURA Shareholders for shares of common stock of the Company.  At closing, Robert Lee, the holder of 30,536,100 shares of common stock, agreed to cancelation of such shares.  Other than Robert Lee, shareholders of Company common stock held 7,625,700 shares.  Also at closing, the Company issued 23,187,876 shares of common stock to the PURA Shareholders.   In addition, shares issuable under outstanding options of PURA – DE will be exercisable into shares of common stock of the Company, pursuant to the terms of such instruments. 

 

As a result of the Share Exchange Agreement and the other transactions contemplated thereunder, PURA is now a wholly owned subsidiary of the Company.

 

The exchange of shares with PURA was accounted for as a reverse acquisition under the purchase method of accounting since PURA obtained control of the Company. Accordingly, the merger of PURA into the Company was recorded as a recapitalization of PURA, PURA being treated as the continuing entity. The historical financial statements presented are the financial statements of PURA.

 

PURA markets and sells a line of cleaning products based on the BeBetterFoam® platform, a revolutionary and proprietary bio-based foam, for consumer kitchen and bathroom, with additional products for outdoor hobbies (fishing and boating, spas and pools), pet care, infant care and industrial use currently under development. BeBetterFoam® is a unique, proprietary polymer process technology that is protected by a trade secret, completely owned by AIRTech and sold to PURA, and is incapable of being reverse engineered.

 

The Bath & Body line and household (including kitchen) sponges are Oleophilic which means, among other things, that it absorbs oil, grease and grime, removes impurities from skin (cleansing and applying/removing make- up), is latex-free.  PURA - DE products are also non-toxic, contain Plant-Based/ renewable resources, have a carbon-negative footprint (removes more carbon than is created), contain no petroleum by-products, use no adhesives or glues, and are infused with soap that is 100% Natural, bio-degradable, sustainable, Vegan, gluten-free, contains botanicals and essential oils; SLS-, Sulfate, Paraben-, and BPA- Free.   The BeBetterFoam® is hydrophobic, which means it resists and does not support bacteria.  PURA - DE believes that the BeBetterFoam® also is up to 40 times stronger than the leading kitchen sponge brand.

 

 

 18 
 

 

 

Pura Marine, the Marine Division of Pura Naturals, offers biologically-based oil-absorbent technologies to the commercial and consumer markets. Working alongside industrial partners, Pura Marine has developed environmentally sustainable oil spill prevention products and solutions targeted towards the marine oil transport, oil refining and trucking industries. Pura Marine also provides plant-based foam products to the recreational boating and fishing industries.

 

Results of Operations

 

Comparison of Results of Operations for the Three Months Ended September 30, 2019 and 2018

 

      Three Months Ended September 30,     Dollar  Percentage
      2019     2018     Change  Change
Sales   $    133,349    $    156,486    $    (23,137)   -14.8%
Cost of goods sold        47,935         72,277         (24,342)   -33.7%
Gross profit        85,414         84,209         1,205    1.4%
Selling expenses        70,489         154,472         (83,983)   -54.4%
General and administrative expenses        570,634         450,362         120,272    26.7%
Interest expense        120,933         303,106         (182,173)   -60.1%
Change in value of derivative liability        (505,679)        2,567,099         (3,072,778)   -119.7%
                                    
Net loss   $    (170,963)   $    (3,390,830)        3,219,867    -95.0%
                                    

 

Sales for the three months ended September 30, 2019 were $133,349, a decrease of $23,137 or 14.8% compared to the same period in 2018.  The decrease was due to periodic sales cycles.

 

Cost of goods sold for the three months ended September 30, 2019 were $47,935 a decrease of $24,342 or 33.7% compared to the same period in 2018.  The decrease in cost of goods was due to a decrease in sales. Cost of goods sold as a percentage of sales was 35.9% for the three months ended September 30, 2019 compared to 46.2% for the same period in 2018.  Cost of goods sold as a percentage of sales decreased due to increases in manufacturing efficiencies.

 

Selling expenses for the three months ended September 30, 2019 were $70,489 a decrease of $83,983 or 54.4% compared to the same period in 2018.  The decrease was due to a decrease in retaining outside marketing consultants and media promotions.

 

General and administrative expenses for the three months ended September 30, 2019 were $570,634 an increase of $120,272 or 26.7% compared to the same period in 2018. The change is due to an increase in compensation expense and professional fees.

 

Interest expense for the three months ended September 30, 2019 was $120,933 a decrease of $182,173 or 60.1% compared to the same period in 2018.  The decrease was mainly due to the decrease in amortization of debt discounts on the convertible notes for the three months ended September 30, 2019 compared to the same period in 2018.

 

 19 
 

 

 

Comparison of Results of Operations for the Nine Months Ended September 30, 2019 and 2018

 

 

   Nine Months Ended September 30,  Dollar  Percentage
   2019  2018  Change  Change
Sales  $294,045   $301,858   $(7,813)   (2.6%)
Cost of goods sold   175,646    164,959   10,687    6.5%
Gross profit   118,399    136,899    (18,500)   (13.5%)
Selling expenses   207,262    245,372    (38,110)   (15.5%)
General and administrative expenses   2,073,460    1,734,666    338,794    19.5%
Interest expense   501,394    957,959    (456,565)   (47.7%)
Change in value of derivative liability   (615,893)   3,028,388    (3,644,281)   (120.3%)
Net loss  $(2,047,824)  $(5,829,486)  $3,781,662    (64.9%)
                     

 

 

Sales for the nine months ended September 30, 2019 were $294,045, a decrease of $7,813 or 2.6% compared to the same period in 2018.  The decrease was due to periodic sales cycles.

 

Cost of goods sold for the nine months ended September 30, 2019 were $175,646 an increase of $10,687 or 6.5% compared to the same period in 2018.  The increase in cost of goods was due to higher manufacturing costs offset by a decrease in sales. Cost of goods sold as a percentage of sales was 59.7% for the nine months ended September 30, 2019 compared to 54.6% for the same period in 2018.  Cost of goods sold increased as a percentage of sales due to an increased cost to manufacture the product.

 

Selling expenses for the nine months ended September 30, 2019 were $207,262 a decrease of $38,110 or 15.5% compared to the same period in 2018.  The decrease was due to a decrease in retaining outside marketing consultants and media promotions.

 

General and administrative expenses for the nine months ended September 30, 2019 were $2,073,460 an increase of $338,794 or 19.5% compared to the same period in 2018. The change is due to an increase in compensation expense offset by a decrease in professional fees. The decrease in professional fees is due to a decrease in fees paid to a strategic consultant.

 

Interest expense for the nine months ended September 30, 2019 was $501,394 a decrease of $456,565 or 47.7% compared to the same period in 2018.  The decrease was mainly due to the decrease in amortization of debt discounts on the convertible notes for the nine months ended September 30, 2019 compared to the same period in 2018.

 

Liquidity and Capital Resources

 

As of September 30, 2019, we had $0 of cash on hand..

 

At September 30, 2019, we had current assets of $187,245 and current liabilities of $3,489,115 resulting in a working capital deficit of $3,301,870. We have experienced losses since our inception. This raises substantial doubt about our ability to continue as a going concern.  The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Net cash used in operating activities was $94,801 during the nine months ended September 30, 2019, compared to $500,646 in net cash used during the nine months ended September 30, 2018.  The decrease in cash used in operating activities is due a decrease in net loss and changes to non-cash expense items for the nine months ended September 30, 2019 compared to the same period in 2018.

 

Cash flows used by investing activities was $0 during the nine months ended September 30, 2019 compared to cash used in investing activities of $1,950 during the nine months ended September 30, 2018.  The decrease in cash used by investing activities is due to trademark acquisition in 2018.

 

Cash flows provided by financing activities were $65,024 during the nine months ended September 30, 2019 compared to $443,184 for the nine months ended September 30, 2018.  The decrease in cash provided by financing activities is principally due to the decrease in proceeds from the issuance of convertible debt.  For the future, we expect to raise money through equity financing via the sale of our common stock or equity-linked securities such as convertible debt. If we cannot raise the money that we need in order to continue to operate our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations.

 

 20 
 

 

 

 Convertible Note Financings

 

On February 8, 2018, the Company issued a 12% Convertible Promissory Note #1 of $103,000, with debt issuance costs of $3,000 to an accredited investor. This convertible note is due and payable on November 20, 2018. The holder has the right from time to time, and at any time during the period beginning on the date which is 180 days following the date of the note and ending on the later of: (i) the maturity date and (ii) the date of payment of the default amount, each in respect of the remaining outstanding principal amount of this note to convert all or any amount of the outstanding and unpaid principal amount of the note into fully paid and non-assessable shares of common stock. The conversion price is 58% of the average of the lowest two trading prices for the common stock during the ten trading day period ending on the latest complete trading day prior to the conversion date.

 

 On March 5, 2018, the Company issued a 12% Convertible Promissory Note #2 of $103,000, with debt issuance costs of $3,000 to an accredited investor. This convertible promissory note #2 is due and payable on December 15, 2018. The holder has the right from time to time, and at any time during the period beginning on the date which is 180 days following the date of the note and ending on the later of: (i) the maturity date and (ii) the date of payment of the default amount, each in respect of the remaining outstanding principal amount of this note to convert all or any amount of the outstanding and unpaid principal amount of the note into fully paid and non-assessable shares of common stock. The conversion price is 61% of the average of the lowest two trading prices for the common stock during the ten trading day period ending on the latest complete trading day prior to the conversion date.

 

On March 6, 2018, the Company issued an 8% Convertible Redeemable Note of $126,000, with debt issuance costs of $6,000 to an accredited investor. This convertible note is due and payable on March 6, 2019. The holder is entitled, at its option, at any time after six months, to convert all or any amount of the principal face amount of this note then outstanding into shares of common stock. The conversion price is 60% of the lowest trading prices for the common stock during the 20 trading day period ending on the latest complete trading day prior to the conversion date.

 

On October 8, 2018, the Company issued two 8% Promissory Note of $50,000 each, with debt issuance costs of $1,000 each, to two accredited investor. This convertible promissory notes are due and payable on April 8, 2019. The holders has the right at any time on or after the maturity date to convert any portion of the outstanding principal and accrued interest into fully paid and non-assessable shares of common stock. The conversion price shall equal the lesser of (i) 80% of the lowest trading price for the common stock during the five trading period ending on the last completed trading day prior to the conversion date or (ii) $0.0065.

 

On November 15, 2018, the Company issued a 0% Promissory Note of $150,000, with original issue discount of $20,000 to an accredited investor. Beginning on February 15, 2019 and continuing on the 15th of every consecutive calendar month for seven months, the Company shall make a cash payment in the amount of $21,429. This convertible promissory note is due and payable on August 15, 2019. The holder has the right at any time on or after the issuance date to convert any portion of the outstanding principal and accrued interest into fully paid and non-assessable shares of common stock. The conversion price is the closing price of the closing price of the Company's common stock on the date the note is funded.

 

On October 8, 2018, the Company issued a 0% Promissory Note of $200,000 for advertising, social media, marketing, consulting, advisory and related services. This convertible promissory note is due and payable on April 8, 2019. The holder has the right at any time on or after the maturity date to convert any portion of the outstanding principal and accrued interest into fully paid and non-assessable shares of common stock. The conversion price shall equal the lesser of (i) 90% of the lowest trading price for the common stock during the five trading period ending on the last completed trading day prior to the conversion date.

 

On January 22, 2019, the Company issued a 12% convertible note payable for $63,000. This convertible note is due and payable on November 15, 2019. The holder has the right to convert any portion of the outstanding principal and accrued interest into fully paid and non-assessable shares of common stock. The conversion price shall equal to 61% of the average of the two lowest trading prices 10 days prior to conversion.

 

 On March 4, 2019, the Company issued a 12% convertible note payable for $53,000. This convertible note is due and payable on December 31, 2019. The holder has the right to convert any portion of the outstanding principal and accrued interest into fully paid and non-assessable shares of common stock. The conversion price shall equal to 61% of the average of the two lowest trading prices 10 days prior to conversion.

 

 21 
 

 

 

Sale of Common Stock

 

On January 18, 2018, the Company sold $5,000 of common stock to an accredited investor. The total amount of common stock sold was 83,333 shares at $0.06 per share.

 

Note Payable

 

The Company entered into a merchant agreement on May 21, 2018. Total payments for the note payable is $40,470, which included $28,500 principal payment and $11,970 interest payment. The note payable requires daily payments of $165, is due on May 21, 2019. The loan is secured by the assets of the Company as defined by Article 9 of the Uniformed Commercial Code and a personal guaranty. The interest rate is 42% per annum.

 

 

The Company entered into a 90 day Secured Convertible Note with Bridgepoint Capital, LLC on August 10, 2018 in the principal amount of $50,000, with no interest accruing. At any time, the principal amount of the note may be converted into any funding or other agreement contemplated at a near future date between the note holder and the Company. The Convertible Note contained an original issue discount of $2,500. For the twelve months ended, $2,500 was amortized.

 

On July 10, 2018, the Company entered into a one year Unsecured Promissory Note in the principal amount of $50,000, with an interest rate of 30% per annum. Five monthly progress payments of $5,000 was due beginning on August 10, 2018. The Company made a payment of $5,000 on November 19, 2018 and December 3, 2018. The Company did not make the progress payments due on October, November and December 10, 2018. As such, this Promissory Note is in default. However, the Holder of the Promissory Note has not declared a default.

 

On March 26, 2019, the Company entered into an unsecured promissory note for net proceeds of $22,515 The note accrues interest at 149% per annum; requires daily repayments of $170 for 248 days and is guaranteed by an officer of the Company.

 

To date, our operations have not generated any profits.  We have funded our operating to date through the sales of common stock and issuance of notes payable and convertible notes payable.  Our ability to continue as a going concern is dependent upon use raising sufficient debt or equity capital to sustain operations until such time as we can generate a profit from our operations.    We are currently working with investors to provide us with the necessary funding, but there can be no assurances we will obtain such funding in the future.  Failure to obtain this additional financing will have a material negative impact on our ability to generate profits in the future.  We anticipate sales will increase during 2019.   As such, our anticipated cash needs to fund operations and pay our notes for the next 12 months is approximately $500,000.

 

Inflation

 

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2019.

 

Critical Accounting Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

 

 22 
 

 

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

 

Accounts Receivable

 

The Company grants credit to customers under credit terms that it believes are customary in the industry and does not require collateral to support customer receivables. The Company currently does not provide an allowance for doubtful collections, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Normal receivable terms vary from 30-90 days after the issuance of the invoice and typically would be considered past due when the term expires. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer.

 

Inventory

 

Inventory is valued at the lower of the inventory's cost (first in, first out basis) or the current market price of the inventory. Management compares the cost of inventory with its market value and an allowance is made to write down inventory to market value, if lower.

 

 

Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment , which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

Revenue Recognition

 

ASU No. 2014-09, Revenue from Contracts with Customers ("Topic 606"), became effective for us on January 1, 2018. We applied the "modified retrospective" transition method for open contracts for the implementation of Topic 606. As sales are and have been primarily through distributors, and we have no significant post-delivery obligations, this did not result in a material recognition of revenue on our accompanying consolidated financial statements for the cumulative impact of applying this new standard. We made no adjustments to our previously-reported total revenues, as those periods continue to be presented in accordance with our historical accounting practices under Topic 605, Revenue Recognition.

 

Deferred Income

 

In some instances, the Company receives payments prior to delivery of its products, whereupon such revenues are deferred until the revenue recognition criteria are met.

 

 23 
 

 

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation . FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee's requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

 

Off-Balance Sheet Arrangements

 

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

 

 

Going Concern

 

The consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates, the realization of assets and satisfaction of liabilities in the normal course of business. We incurred losses from operations of $2,162,323 for the nine months ended September 30, 2019 and $3,394,068 for the year ended December 31, 2018, and had an accumulated deficit of $15,959,955 at September 30, 2019. In addition, we used cash from operating activities of $94,801 for the nine months ended September 30, 2019.  These factors raise substantial doubt about our ability to continue as a going concern.

 

The Company will require additional funding to execute its future strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue adequate to support its cost structure. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

 

While the Company is attempting to establish an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern, the Company’s cash position may not be adequate to support the Company’s daily operations. Management intends to raise additional funds by seeking equity and/or debt financing; however there can be no assurances that it will be successful in those efforts. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to obtain financing, further implement its business plan, and generate revenues.

There are significant risks and uncertainties which could negatively affect the Company’s operations. These are principally related to the existence of events of default under the Company’s outstanding debt obligations, which could trigger penalties. Furthermore, if our current indebtedness is not restructured, paid or converted into equity, which is at the debt holder’s discretion, our current operations do not generate sufficient cash to pay interest and principal on these obligations when they become due. Accordingly, there can be no assurance that we will be able to pay these or other obligations which we may incur in the future. In the event we are unable to restructure, pay or convert into equity the balance of our outstanding indebtedness, the holders may obtain judgments against us and seek to enforce such judgments against our assets, in which event we will be required to cease our business activities and the equity of our stockholders will be effectively wiped out.

Our only sources of additional funds to meet continuing operating expenses, fund additional research and development and fund additional working capital are through the sale of securities, and/or debt instruments. We are actively seeking additional debt or equity financing, but no assurances can be given that such financing will be obtained or what the terms thereof will be. We may need to discontinue a portion or all of our operations if we are unsuccessful in generating positive cash flow or financing for our operations through the issuance of securities.

 

The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

 24 
 

 

 

 

Recent Accounting Pronouncements

 

In June 2018, the FASB issued Accounting Standards Update (“ASU”) ASU 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to nonemployees with the requirements for share-based payments granted to employees. ASU 2018-07 is effective on January 1, 2019. Early adoption is permitted. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods in fiscal years beginning after December 15, 2018, with early adoption permitted. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements as the Company did not have any leases covered by this new ASU.

 

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future  financial statements.

 

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

 

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures      As of the end of period covered by this report, the Company carried out an evaluation, with the participation of the Company's Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company's disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, the Company's Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934, as amended ("Exchange Act") Rule 13a15(e)) as of September 30, 2019, are not effective, due to lack of segregation of duties and ineffective controls over period end financial disclosures and reporting processes, based on the evaluation of these controls and procedures required by paragraph (b) of Rule 13a15. 

 

Changes in Internal Control over Financial Reporting   –   There were no changes in our internal control over financial reporting during the quarter ended September 30, 2019, which were identified in conjunction with management's evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 25 
 

 

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business.

 

The Company was named in a lawsuit in Hawaii entitled Yen, et al. v. Advanced Innovative Marketing, Inc., et al. Although the Company has not been dismissed yet from the lawsuit, the Company believes there is no merit to the case and that the Company never should have been named as a party. The Company is represented by counsel and the Company is currently seeking a full dismissal.

 

The Company is defending the Pura Naturals Pet, Pura Pet and Pura Tips trademarks in a trademark cancellation proceeding brought my Nxt Generation Pet, Inc. challenging these marks. The parties have conducted discovery and submitted evidence to the USPTO. The matter is set for hearing on the merits in 2020. The Company is optimistic that the Company will prevail in the cancellation dispute. However, at this time, no judicial determination has been made by the USPTO and the Company cannot state with certainty the likely outcome one way or another. The Company is confident that the adverse party will not obtain the marks in the cancellation proceeding or through separate application for the marks.

 

The Company and the law firm of Sheppard, Mullin, Richter and Hampton are involved in a legal proceeding in The Superior Court of the State of California concerning unpaid legal fees billed by the law firm to the Company. The Company and the law firm have settled. The Company agreed through settlement to pay an amount certain that is owed through monthly installment payments.

 

The Company and the law firm of Ellenoff, Grosman and Schole are involved in a legal proceeding in the State of New York concerning unpaid legal fees billed by the law firm to the Company. A judgment against the company was recently entered. The Company will be seeking to set aside the judgment and/or resolve this matter in the near future.

 

 26 
 

 

 

Item 1A.  Risk Factors

 

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the quarter ended September 30, 2019, the Company issued 123,980,651 shares for the conversion of $111,115 of convertible notes payable; and issued 138,807,619 shares to officers for compensation valued at $291,496.

 

The above issuances in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), as set forth in Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.

 

Item 3. Defaults Upon Senior Securities.

 

None

 

Item 4.  Mine Safety Disclosures

 

Not applicable

 

 

Item 5.  Other Information

 

Not applicable

 

Item 6. Exhibits.

 

 27 
 

 

Exhibit No.   Description
3.1   Articles of Incorporation (incorporated herein by reference from Exhibit 3.1 to Registrant's Registration Statement on Form S-1 filed with the SEC on December 15, 2010)
3.2   Articles of Amendment to Articles of Incorporation ( incorporated herein by reference from Exhibit 3.4 to Registrant's Registration Statement on Form S-1 filed with the SEC on December 15, 2010)
3.3   Articles of Amendment of Amended Articles of Incorporation (incorporated herein by reference from Exhibit 3.1 to Registrant's Current Report on Form 8-K filed with the SEC on November 21, 2016) .
3.4   By-Laws (incorporated herein by reference from Exhibit 3.2 to Registrant's Registration Statement on Form S-1 filed with the SEC on December 15, 2010)
21.1   Subsidiaries of the registrant .*
31.1   Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .*
31.2   Certification of Principal Accounting Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *
32.1   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .*
32.2   Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .*
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Labels Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document


  * Filed herewith

 

 

 28 
 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on January 21, 2020.

 

 

 

  PURA NATURALS, INC.  
     
     
 By:   /s/ Robert Doherty    
 

Robert Doherty, Chief Executive Officer

 

 
     
     

 

 

 

 29